Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363631 · ClinicalTrials.gov registry record · Phase 1
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
A Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic, sponsored by Mohammed Milhem.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05363631 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic that is active but no longer recruiting, run by Mohammed Milhem. The registered enrollment target is 55 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05363631, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic, is active but no longer recruiting, sponsored by Mohammed Milhem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Axitinib
- DRUG Selenomethionine (SLM)
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363631
The ClinicalTrials.gov registry entry for NCT05363631 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05363631 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05363631 about?
NCT05363631 is a clinical study titled "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab". The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
What is the current status of trial NCT05363631?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2022-09-19. Estimated completion is 2026-12-31.
What conditions does trial NCT05363631 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic.
What interventions are being tested in trial NCT05363631?
The interventions under investigation include: Pembrolizumab (DRUG), Axitinib (DRUG), Selenomethionine (SLM) (DRUG).
Who is sponsoring clinical trial NCT05363631?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05363631 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Clear Cell Renal Cell Carcinoma
All registered trials for this condition
Clear Cell Renal Cell Carcinoma Metastatic
All registered trials for this condition
Iowa
All trials with a study site in Iowa
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.